Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2043-2051, 2005. First published September 1, 2005; 10.1373/clinchem.2005.053942
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.053942v1
51/11/2043    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allard, L.
Right arrow Articles by Sanchez, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allard, L.
Right arrow Articles by Sanchez, J.-C.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:2043-2051.)
© 2005 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the Early Diagnosis of Stroke

Laure Allard1,a, Pierre R. Burkhard2, Pierre Lescuyer1, Jennifer A. Burgess1, Nadia Walter1,3, Denis F. Hochstrasser1,3,4 and Jean-Charles Sanchez1,3

1 Biomedical Proteomics Research Group, Department of Structural Biology and Bioinformatics, Medical and University Center, Geneva, Switzerland.
2 Neurology Department, and 3 Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, Geneva, Switzerland.
4 Pharmacy Section, Faculty of Sciences, Geneva University, Geneva, Switzerland.

aAddress correspondence to this author at: Biomedical Proteomics Research Group, DBSB/CMU, Rue Michel Servet, 1, CH-1211 Geneva 4, Switzerland. Fax 41-0-22-379-59-84; e-mail laure.allard{at}medecine.unige.ch.

Background: Plasma markers for stroke could be useful in diagnosis and prognosis and in prediction of response of stroke patients to therapy. PARK7 and nucleoside diphosphate kinase A (NDKA) are increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke.

Methods: We used ELISA to measure PARK7 and NDKA in plasma in 3 independent European and North American retrospective studies encompassing a total of 622 stroke patients and 165 control individuals.

Results: Increases in both biomarkers were highly significant, with sensitivities of 54%–91% for PARK7 and 70%–90% for NDKA and specificities of 80%–97% for PARK7 and 90%–97% for NDKA. The concentrations of both biomarkers increased within 3 h of stroke onset.

Conclusions: PARK7 and NDKA may be useful plasma biomarkers for the early diagnosis of stroke. In addition, this study demonstrated the utility of analysis of postmortem CSF proteins as a first step in the discovery of plasma markers of ischemic brain injury.




The following articles in journals at HighWire Press have cited this article:


Home page
 NeurologyHome page
C. Foerch, J. Montaner, K. L. Furie, M. M. Ning, and E. H. Lo
Invited Article: Searching for oracles?: Blood biomarkers in acute stroke
Neurology, August 4, 2009; 73(5): 393 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J.-M. Lee, K. Blennow, N. Andreasen, O. Laterza, V. Modur, J. Olander, F. Gao, M. Ohlendorf, and J. H. Ladenson
The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients
Clin. Chem., October 1, 2008; 54(10): 1617 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
W. Whiteley, M.-C. Tseng, and P. Sandercock
Blood Biomarkers in the Diagnosis of Ischemic Stroke: A Systematic Review
Stroke, October 1, 2008; 39(10): 2902 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. J. Finehout, Z. Franck, N. Relkin, and K. H. Lee
Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem Interval
Clin. Chem., October 1, 2006; 52(10): 1906 - 1913.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. L. Hortin, S. A. Jortani, J. C. Ritchie Jr, R. Valdes Jr, and D. W. Chan
Proteomics: A New Diagnostic Frontier
Clin. Chem., July 1, 2006; 52(7): 1218 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
A. Chamorro and J. Hallenbeck
The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease
Stroke, February 1, 2006; 37(2): 291 - 293.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. D. Hill
Diagnostic Biomarkers for Stroke: A Stroke Neurologist's Perspective
Clin. Chem., November 1, 2005; 51(11): 2001 - 2002.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.